Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies

Oncologist

Volumn 14, Issue 2, 2009, Pages 119-124

  Guarino, Michael J ^a   Schneider, Charles J ^a   Hosford, Martha A ^a   Brahmer, Julie R ^b   Rudin, Charles M ^b   Finckenstein, Friedrich Graf ^c   Philip Norton, Robyn E ^d   Lu, Haolan ^c   Weber, Martin R ^c   Ettinger, David S ^b  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OSI Pharmaceuticals   (United States)

Author keywords

Cetuximab; Erlotinib; Phase I; Solid malignancies

Indexed keywords

CETUXIMAB; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EYE PAIN; FATIGUE; FEVER; GLOSSODYNIA; HEADACHE; HUMAN; HYPESTHESIA; HYPOCALCEMIA; HYPOMAGNESEMIA; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN PAIN; SKIN TOXICITY; SOLID TUMOR; UTERINE CERVIX CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 64149095095     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0124     Document Type: Article

References (23)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Mendelsohn J, Baselga J. Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
3. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
5. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squa-mous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
6. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
7. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
8. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the an-tiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
9. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for re-current and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578 - 5587.
10. Thienelt CD, Bunn PA Jr, Hanna N et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786-8793.
11. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study ofcetux-imab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-369.
12. Herbst RS, Chansky K, Kelly K et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer(NSCLC): Final report of SWOG 0342. Proc Am Soc Clin Oncol 2007; 25(suppl 18):7545.
13. Butts CA, Bodkin D, Middleman EL et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-5784.
14. Lynch T, Patel T, Dreisbach L et al. A randomized multicenter phase III study of cetuximab(Erbitux®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with ad-vanced/metastatic non-small cell lung cancer(NSCLC). J Thorac Oncol 2007;2(suppl 4):S340-S341.
15. Pirker R, Szczesna A, Von Pawell J et al. FLEX: A randomized, multi-center, phase III study of cetuximab in combination with cisplatin/vinorel-bine(CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer(NSCLC)[abstract]. J Clin Oncol 2008;27:3.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
17. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
18. Jimeno A, Rubio-Viqueira B, Amador ML et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005;65:3003-3010.
19. Huang S, Armstrong EA, Benavente S et al. Dual-agentmoleculartargeting of the epidermal growth factor receptor(EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64:5355-5362.
20. Matar P, RojoF, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib(ZD1839) and the monoclonal antibody cetuximab(IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487-6501.
21. Baselga J, Schoffski, Rojo F et al. A phase I pharmacokinetic(PK) and mo-lecularpharmacodynamic(PD) study ofthecombinationoftwoanti-EGFR therapies, the monoclonal antibody(MAb) cetuximab(C) and the tyrosine kinase inhibitor(TKI) gefitinib(G), in patients(pts) with advanced colo-rectal cancer(CRC), head and neck(HNC) and non-small cell lung cancer(NSCLC). Proc Am Soc Clin Oncol 2006;24(suppl 18):3006.
22. Preston GG, Calvo E, Papadopoulos K et al. Multi-targeted inhibition of the epidermal growth factor receptor(EGFR) and vascular endothelial growth factor receptor(VEGFR) pathways: A phase I study of cetuximab(C), erlotinib(E), and bevacizumab(B) in patients with solid tumors. Proc Am Soc Clin Oncol 2006;24(suppl 18):3005.
23. Tan AR, Moore DF, Hidalgo M et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006;12:6517-6522.